Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adele Salemme

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
European Journal of Dermatology : EJD|March 1, 2023
Anti-laminin 332 antibody detection using biochip immunofluorescence microscopy in a real-life cohort of Italian patients with mucous membrane pemphigoidGiulia Gasparini, Emanuele Cozzani, Giovanni Di Zenzo, et al.
Archives of Dermatological Research|February 10, 2023
Pilot study investigating BP-180 in extracellular vesicles derived from blister fluid of bullous pemphigoid patientsGiulia Gasparini, Roberta Tasso, Maria Elisabetta Federica Palamà, et al.
Acta Dermato-Venereologica|February 4, 2020
Autoantibody Profile of a Cohort of 54 Italian Patients with Linear IgA Bullous Dermatosis: LAD-1 Denoted as a Major Auto-antigen of the Lamina Lucida SubtypeEmanuele Cozzani, Giovanni Di Zenzo, Giulia Gasparini, et al.
Frontiers in Medicine|August 30, 2021
Case Report: Management of Malignancy-Exacerbated Pemphigus Vulgaris During COVID-19 PandemicAlberto Corrà, Francesca Cammelli, Lavinia Quintarelli, et al.
Journal of the American Academy of Dermatology|May 22, 2026
Linagliptin is a risk factor for bullous pemphigoid associated with BP180-NC16A/BP230 seronegativity and milder severity: evidence from a prospective case-control study supporting ECD-BP180 ELISA in reducing diagnostic delayAnna Pira, Adele Salemme, Feliciana Mariotti, et al.
Journal of the American Academy of Dermatology|March 3, 2022
Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and -BP230 humoral response: Results of a multicenter studyAdele Salemme, Luca Fania, Alessandra Scarabello, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
European Journal of Dermatology : EJD|March 1, 2023
Anti-laminin 332 antibody detection using biochip immunofluorescence microscopy in a real-life cohort of Italian patients with mucous membrane pemphigoidGiulia Gasparini, Emanuele Cozzani, Giovanni Di Zenzo, et al.
Archives of Dermatological Research|February 10, 2023
Pilot study investigating BP-180 in extracellular vesicles derived from blister fluid of bullous pemphigoid patientsGiulia Gasparini, Roberta Tasso, Maria Elisabetta Federica Palamà, et al.
Acta Dermato-Venereologica|February 4, 2020
Autoantibody Profile of a Cohort of 54 Italian Patients with Linear IgA Bullous Dermatosis: LAD-1 Denoted as a Major Auto-antigen of the Lamina Lucida SubtypeEmanuele Cozzani, Giovanni Di Zenzo, Giulia Gasparini, et al.
Frontiers in Medicine|August 30, 2021
Case Report: Management of Malignancy-Exacerbated Pemphigus Vulgaris During COVID-19 PandemicAlberto Corrà, Francesca Cammelli, Lavinia Quintarelli, et al.
Journal of the American Academy of Dermatology|May 22, 2026
Linagliptin is a risk factor for bullous pemphigoid associated with BP180-NC16A/BP230 seronegativity and milder severity: evidence from a prospective case-control study supporting ECD-BP180 ELISA in reducing diagnostic delayAnna Pira, Adele Salemme, Feliciana Mariotti, et al.
Journal of the American Academy of Dermatology|March 3, 2022
Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and -BP230 humoral response: Results of a multicenter studyAdele Salemme, Luca Fania, Alessandra Scarabello, et al.
Pageof 2